<DOC>
	<DOCNO>NCT00177047</DOCNO>
	<brief_summary>This study regimen melphalan autologous stem cell patient multiple myeloma . We hypothesize particular regimen improve survival patient .</brief_summary>
	<brief_title>Autologous Transplant Multiple Myeloma</brief_title>
	<detailed_description>Before start treatment study , bone marrow transplant ( BMT ) doctor check subject 's general health . Subjects follow test evaluation find participate : -- Medical history physical examination , include height weight. -- Blood test ( approximately 4 - 5 tablespoon ) -- Urine test -- Chest x-ray -- Electrocardiogram ( ECG EKG ) -- Heart Scan ( MUGA ) -- Pulmonary Function Test ( PFT ) -- Bone marrow biopsy aspirate . -- If Female subject child-bearing age serum pregnancy test perform . After eligible patient completely stag exercised consent , may undergo one cycle chemotherapy ( cyclophosphamide Mesna ) growth factor ( G-CSF ) effect cytoreduction mobilization PBSC collection . All patient receive high-dose melphalan follow autologous stem cell transplant ( SCT ) . Blood test perform frequently evaluate subject 's response treatment possible side effect treatment . If necessary , platelet red cell transfusion give maintain adequate level antibiotic give treat prevent infection . Subjects may also require intravenous nutritional support pain medication transplantation . The study coordinator collect health information three year . They collect information every week 100 day , 6 month , 1 year , 2 year , 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Patients meet Durie Salmon criterion initial diagnosis multiple myeloma , require therapy meet one following : After initial therapy either first complete partial remission objective response After achieve initial response later disease progression , patient eligible subsequent therapy upon achievement either complete partial response Is eligible refused protocol high priority 18 75 year age Adequate organ function define : Hematologic : hemoglobin ≥ 8 gm/dl ( untransfused ) , white blood cell ( WBC ) ≥ 3000/μl , absolute neutrophil count ( ANC ) ≥ 1500/μl , platelet ≥ 100,000/μl ( untransfused ) Cardiac : active ischemia , leave ventricular ejection fraction &gt; 45 % MUGA scan Hepatic : bilirubin &lt; 2.0 mg/dl , ALT &lt; 3x upper limit normal Pulmonary : FEV1Forced Expiratory Volume One Second AND Forced vital capacity ( FVC ) &gt; 50 % predicted Carbon Monoxide Diffusing Capacity ( DLCO ) ( correct ) &gt; 50 % predict Performance status : Karnofsky performance &gt; 80 % . Free active uncontrolled infection time study entry . At time study enrollment &gt; 4 week prior myelosuppressive chemotherapy ; &gt; 6 week prior nitrosoureas . Patients must exercise informed voluntary consent sign consent form approve University Minnesota IRB : Human Subjects Committee . Patients ineligible advanced myeloma refractory unresponsive salvage chemotherapy regimen . Female patient pregnant ( positive bHCG ) breastfeeding exclude study entry . In addition fertile men woman unwilling use contraceptive technique 12 month follow treatment , particularly thalidomide also exclude study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stem cell transplantation</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>autologous</keyword>
</DOC>